AR070416A1 - Asociacion de un inhibidor de corriente sinusal if y de un beta-bloqueante - Google Patents

Asociacion de un inhibidor de corriente sinusal if y de un beta-bloqueante

Info

Publication number
AR070416A1
AR070416A1 ARP090100483A ARP090100483A AR070416A1 AR 070416 A1 AR070416 A1 AR 070416A1 AR P090100483 A ARP090100483 A AR P090100483A AR P090100483 A ARP090100483 A AR P090100483A AR 070416 A1 AR070416 A1 AR 070416A1
Authority
AR
Argentina
Prior art keywords
beta
association
current inhibitor
sinusal
blocking
Prior art date
Application number
ARP090100483A
Other languages
English (en)
Inventor
Guy Lerebours-Pigeonniere
Jean-Henri Calvet
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39666229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR070416(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR070416A1 publication Critical patent/AR070416A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Asociacion fija de un inhibidor de corriente sinusal lf y de un beta-bloqueante. Reivindicacion 2: Asociacion segun la reivindicacion 1, caracterizada porque el inhibidor de corriente sinusal lf es la ivabradina o 3-{3-[{[(7S)-3,4-dimetoxibiciclo[4.2.0]octa-1,3,5-trien-7-il]metil}(metil)amino]propil}-7,8-di-metoxi-1,3,4,5-tetrahidro-2H-3-benzazepin-2-ona, o uno de sus hidratos, formas cristalinas o sales de adicion a un ácido aceptable farmacéuticamente. Reivindicacion 5: Asociacion segun una de las reivindicaciones 1 a 4, caracterizada porque el beta-bloqueante es el atenolol, o uno de sus hidratos, formas cristalinas o sales de adicion a un ácido aceptable farmacéuticamente.
ARP090100483A 2008-02-14 2009-02-12 Asociacion de un inhibidor de corriente sinusal if y de un beta-bloqueante AR070416A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0800800A FR2927538B1 (fr) 2008-02-14 2008-02-14 Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.

Publications (1)

Publication Number Publication Date
AR070416A1 true AR070416A1 (es) 2010-04-07

Family

ID=39666229

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100483A AR070416A1 (es) 2008-02-14 2009-02-12 Asociacion de un inhibidor de corriente sinusal if y de un beta-bloqueante

Country Status (38)

Country Link
US (1) US8217030B2 (es)
EP (2) EP2409694A1 (es)
JP (2) JP2009191069A (es)
KR (1) KR101078133B1 (es)
CN (1) CN101507726B (es)
AP (1) AP2010005366A0 (es)
AR (1) AR070416A1 (es)
AU (1) AU2009200393B2 (es)
BR (1) BRPI0900470A2 (es)
CA (1) CA2654210C (es)
CO (1) CO6290712A2 (es)
CR (1) CR11628A (es)
CU (1) CU24007B1 (es)
CY (1) CY1114113T1 (es)
DK (1) DK2090303T3 (es)
EA (1) EA200900137A1 (es)
EC (1) ECSP10010402A (es)
ES (1) ES2421893T3 (es)
FR (1) FR2927538B1 (es)
GE (1) GEP20115261B (es)
HK (1) HK1137341A1 (es)
HN (1) HN2010001608A (es)
HR (1) HRP20130617T1 (es)
IL (1) IL207386A0 (es)
MA (1) MA31132B1 (es)
ME (1) ME01014B (es)
MX (1) MX2009001590A (es)
MY (1) MY149122A (es)
NI (1) NI201000139A (es)
NZ (1) NZ574843A (es)
PL (1) PL2090303T3 (es)
PT (1) PT2090303E (es)
RS (1) RS52834B (es)
SG (1) SG155130A1 (es)
SI (1) SI2090303T1 (es)
UA (1) UA99817C2 (es)
WO (1) WO2009115669A1 (es)
ZA (1) ZA200900894B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
US9674435B1 (en) * 2016-07-06 2017-06-06 Lawrence Maxwell Monari Virtual reality platforms for capturing content for virtual reality displays
KR20190001340A (ko) * 2017-06-27 2019-01-04 에리슨제약(주) 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503510A (ja) * 1989-11-21 1993-06-10 セプラカー・インコーポレーテツド 光学的に純粋な(s)―アテノロールを含む組成物と方法
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
EP1426051B1 (en) * 2001-09-11 2008-07-16 Asahi Kasei Pharma Corporation Medicinal composition for prevention of or treatment for cerebrovascular disorder
PT1362590E (pt) 2002-07-25 2004-05-31 Boehringer Ingelheim Pharma Utilizacao de cilobradina ou dos seus sais farmaceuticamente aceitaveis para o tratamento ou prevencao de falha cardiaca
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
CN101095682A (zh) * 2007-07-23 2008-01-02 北京本草天源药物研究院 一种伊伐布雷定或其药用盐的口服制剂

Also Published As

Publication number Publication date
CN101507726A (zh) 2009-08-19
NZ574843A (en) 2011-07-29
ZA200900894B (en) 2009-12-30
US20090209515A1 (en) 2009-08-20
CY1114113T1 (el) 2016-07-27
CN101507726B (zh) 2012-03-28
IL207386A0 (en) 2010-12-30
KR20090088328A (ko) 2009-08-19
SG155130A1 (en) 2009-09-30
NI201000139A (es) 2011-01-10
HRP20130617T1 (en) 2013-07-31
RS52834B (en) 2013-10-31
GEP20115261B (en) 2011-08-10
US8217030B2 (en) 2012-07-10
ES2421893T3 (es) 2013-09-06
FR2927538B1 (fr) 2010-02-19
CU24007B1 (es) 2014-06-27
FR2927538A1 (fr) 2009-08-21
AU2009200393A1 (en) 2009-09-03
CA2654210A1 (fr) 2009-08-14
MX2009001590A (es) 2009-08-24
ME01014B (me) 2012-10-20
HK1137341A1 (en) 2010-07-30
MA31132B1 (fr) 2010-02-01
HN2010001608A (es) 2013-10-07
CA2654210C (fr) 2013-06-25
CU20100162A7 (es) 2011-10-31
UA99817C2 (ru) 2012-10-10
EP2090303A1 (fr) 2009-08-19
JP2012211179A (ja) 2012-11-01
SI2090303T1 (en) 2013-08-30
DK2090303T3 (da) 2013-07-29
BRPI0900470A2 (pt) 2009-09-29
EP2090303B1 (fr) 2013-05-01
MY149122A (en) 2013-07-15
PT2090303E (pt) 2013-05-31
AU2009200393B2 (en) 2013-11-07
PL2090303T3 (pl) 2013-07-31
ECSP10010402A (es) 2010-09-30
AP2010005366A0 (en) 2010-08-31
CO6290712A2 (es) 2011-06-20
EP2409694A1 (fr) 2012-01-25
KR101078133B1 (ko) 2011-10-28
EA200900137A1 (ru) 2009-10-30
WO2009115669A1 (fr) 2009-09-24
JP2009191069A (ja) 2009-08-27
CR11628A (es) 2010-11-22

Similar Documents

Publication Publication Date Title
CR7691A (es) Nuevo procedimiento de sintesis de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
EA200901051A1 (ru) Новый способ разделения энантиомеров (3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-ил)нитрила и применение при синтезе ивабрадина
EA201201525A1 (ru) Промышленный способ синтеза солей ивабрадина
JO2807B1 (en) A new process for the synthesis of ivabradine and its addition salts with pharmaceutically acceptable acid.
AR070416A1 (es) Asociacion de un inhibidor de corriente sinusal if y de un beta-bloqueante
RS54838B1 (sr) Sprega n-{[(7s)-3,4-dimetoksibiciklo[4.2.0]okta-1,3,5-trien-7-il]metil}-3-(7,8-dimetoksi-1,2,4,5-tetrahidro-3h-3-benzazepin-3-il)-n-metil-3-okso-1-propanamina i perindoprila
AR073031A1 (es) Composiciones terapeuticas que contienen macitentan
CO5790168A1 (es) Nueva asociacion de un inhibidor de la corriente sinusual if y de un inhibidor de la enzima de conversion y las composiciones farmaceuticas que la contienen
MY146245A (en) New process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
EA201101147A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
PE20110098A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
AR058575A1 (es) Asociacion de un inhibidor de la corriente sinusal if y de un inhibidor calcico y las composiciones farmaceuticas que la contienen
GEP20135970B (en) New method of synthesis of ivabradine and pharmaceutically acceptable acid-additive salts thereof
CY1116500T1 (el) Μεθοδος ενζυματικης συνθεσης toy (7s)-1-(3,4-διμεθοξυδικυκλο[4.2.0] οκτα-1,3,5-τριεν-7-υλ)-ν-μεθυλομεθαναμινης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων αυτης
EA200800022A3 (ru) Применение ивабрадина для получения лекарственного средства, предназначенного для лечения эндотелиальной дисфункции
EA201000397A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
CL2011000297A1 (es) Procedimiento de sintesis de ivabradina utilizando un intermediario de hemitioacetal; y los compuestos intermediarios considerados.
MD20130008A2 (en) Process for the enzymatic synthesis of (7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid or esters thereof, and application in the synthesis of ivabradine and salts thereof
NZ622915A (en) Process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one compounds, and application in the synthesis of ivabradine
MD4468B1 (ro) Procedeu de sinteză prin lactamizare a ivabradinei şi a sărurilor sale de adiţie cu acizi acceptabili farmaceutic
TH137164A (th) การใช้ประโยชน์จากการร่วมกันของสารยับยั้งกระแสไซนัสโหนด If (sinus node If current inhibitor) และสารยับยั้งเอนไซม์ซึ่งเปลี่ยนผันแองจิโอเทนซิน (angiotensin-converting enzyme inhibitor) ในการบำบัดภาวะหัวใจล้มเหลว
EA200901369A1 (ru) Применение ивабрадина в качестве диагностического средства в методе коронарной ангиографии путем многослойной компьютерной томографии
TH137164B (th) การใช้ประโยชน์จากการร่วมกันของสารยับยั้งกระแสไซนัสโหนด If (sinus node If current inhibitor)และสารยับยั้งเอนไซม์ซึ่งเปลี่ยนผันแองจิโอเทนซิน(angiotensin-converting enzyme inhibitor)ในการบำบัดภาวะหัวใจล้มเหลว
WO2011075799A3 (en) Oral antidepressant formulation
TH107683B (th) กระบวนการใหม่สำหรับการสังเคราะห์อิวาเบรดีนและเกลือการเติมของสารนี้พร้อม ด้วยกรดที่ยอมรับได้โดยทางเภสัชภัณฑ์

Legal Events

Date Code Title Description
FB Suspension of granting procedure